Roche Pays $75M for Simcere Cancer Drug
Roche has agreed to pay seventy five million dollars upfront to Simcere Pharmaceutical for exclusive global rights to an experimental preclinical blood cancer drug. The Chinese drugmaker could also receive up to one point four six billion dollars in potential milestone payments.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR will pay $75 million upfront to SIMCERE PHARMACEUTICAL GROUP for global rights to an experimental blood cancer drug. The deal marks a major pipeline expansion for the Switzerland-based healthcare giant into early-stage oncology. The partnership provides the China-based drugmaker with up to $1.46 billion in potential milestone payments.
